Radiopharm Theranostics Ltd (AU:RAD) — Market Cap & Net Worth
Market Cap & Net Worth: Radiopharm Theranostics Ltd (RAD)
Radiopharm Theranostics Ltd (AU:RAD) has a market capitalization of $31.38 Million (AU$44.35 Million) as of May 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23575 globally and #938 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Radiopharm Theranostics Ltd's stock price AU$0.02 by its total outstanding shares 2333980142 (2.33 Billion). Analyse RAD cash flow conversion to see how efficiently the company converts income to cash.
Radiopharm Theranostics Ltd Market Cap History: 2021 to 2026
Radiopharm Theranostics Ltd's market capitalization history from 2021 to 2026. Data shows change from $595.51 Million to $31.38 Million (-48.67% CAGR).
Radiopharm Theranostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Radiopharm Theranostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.08x
Radiopharm Theranostics Ltd's market cap is 3.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $163.82 Million | $8.83K | -$30.34 Million | 18550.88x | N/A |
| 2023 | $122.21 Million | $292.36K | -$34.61 Million | 418.00x | N/A |
| 2024 | $39.63 Million | $299.23K | -$47.95 Million | 132.46x | N/A |
| 2025 | $41.29 Million | $13.40 Million | -$36.70 Million | 3.08x | N/A |
Competitor Companies of RAD by Market Capitalization
Companies near Radiopharm Theranostics Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Radiopharm Theranostics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Radiopharm Theranostics Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Radiopharm Theranostics Ltd's market cap moved from $595.51 Million to $ 31.38 Million, with a yearly change of -48.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$31.38 Million | -24.00% |
| 2025 | AU$41.29 Million | +4.17% |
| 2024 | AU$39.63 Million | -67.57% |
| 2023 | AU$122.21 Million | -25.40% |
| 2022 | AU$163.82 Million | -72.49% |
| 2021 | AU$595.51 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Radiopharm Theranostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.38 Million USD |
| MoneyControl | $31.38 Million USD |
| MarketWatch | $31.38 Million USD |
| marketcap.company | $31.38 Million USD |
| Reuters | $31.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more